Agnieszka K. Witkiewicz

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Figure S1 from Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RAS<sup>mut</sup> Disease Models

  2026-06-17

• Supplementary Table S2 from Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RAS<sup>mut</sup> Disease Models

  2026-06-17

• Supplementary Figure S3 from Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RAS<sup>mut</sup> Disease Models

  2026-06-17

• Figure S1 from Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222

  2026-06-17

• Figure S7 from Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222

  2026-06-17

• Supplementary Table S4 from Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RAS<sup>mut</sup> Disease Models

  2026-06-17

• Figure S5 from Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222

  2026-06-17

• Supplementary Figure S2 from Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RAS<sup>mut</sup> Disease Models

  2026-06-17

• Figure S2 from Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222

  2026-06-17

• Supplementary Figure S6 from Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RAS<sup>mut</sup> Disease Models

  2026-06-17

• Supplementary Table S1 from Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RAS<sup>mut</sup> Disease Models

  2026-06-17

• Supplementary Table S3 from Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RAS<sup>mut</sup> Disease Models

  2026-06-17

• Figure S6 from Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222

  2026-06-17

• Figure S4 from Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222

  2026-06-17

• Figure S3 from Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222

  2026-06-17

• Supplementary Figure S4 from Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RAS<sup>mut</sup> Disease Models

  2026-06-17

• Supplementary Figure S5 from Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RAS<sup>mut</sup> Disease Models

  2026-06-17

• The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond

  Nature Reviews Drug Discovery · 2026-04-27 · 2 citations

• Cyclin E modulates vulnerability to CDC7 kinase inhibition

  Oncogenesis · 2026-04-24

• Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort

  Modern Pathology · 2026-04-21